Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Personalized CFTR Modulator Therapy for G85E and N1303K Homozygous Patients with Cystic Fibrosis
Simon Y. Graeber, Anita Balázs, Niklas Ziegahn, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12365-12365
Open Access | Times Cited: 19

Showing 19 citing articles:

Cystic fibrosis
Marcus Mall, Pierre–Régis Burgel, Carlo Castellani, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 27
Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rareCFTRvariants: a viewpoint
Pierre‐Régis Burgel, Isabelle Sermet‐Gaudelus, Emmanuelle Girodon, et al.
European Respiratory Journal (2024) Vol. 63, Iss. 1, pp. 2301959-2301959
Closed Access | Times Cited: 19
The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study
Pierre–Régis Burgel, Isabelle Sermet‐Gaudelus, Emmanuelle Girodon, et al.
The Lancet Respiratory Medicine (2024) Vol. 12, Iss. 11, pp. 888-900
Closed Access | Times Cited: 10
Laboratory Tools to Predict CFTR Modulator Therapy Effectiveness and to Monitor Disease Severity in Cystic Fibrosis
Mafalda Bacalhau, Mariana Camargo, Miquéias Lopes‐Pacheco
Journal of Personalized Medicine (2024) Vol. 14, Iss. 1, pp. 93-93
Open Access | Times Cited: 5
Elexacaftor/Tezacaftor/Ivacaftor Efficacy in a Cohort of Italian Patients with CFTR Rare Mutations
Francesca Lucca, Sonia Volpi, Mirco Ros, et al.
International Journal of Translational Medicine (2025) Vol. 5, Iss. 1, pp. 11-11
Open Access
Progress of personalized medicine of cystic fibrosis in the times of efficient CFTR modulators
Burkhard Tümmler, Sophia T. Pallenberg, Anna‐Maria Dittrich, et al.
Molecular and Cellular Pediatrics (2025) Vol. 12, Iss. 1
Open Access
The clinical effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) for people with CF without a F508del variant: A systematic review and meta-analysis
Dániel Lupas, Frank Y. Chou, Mohammad Abdullah Al Hakani, et al.
Journal of Cystic Fibrosis (2024) Vol. 23, Iss. 5, pp. 950-958
Closed Access | Times Cited: 3
Elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and rare mutations
Valentina Fainardi, Federico Cresta, Claudio Sorio, et al.
Pediatric Pulmonology (2024)
Open Access | Times Cited: 2
Changing profile of bacterial infection and microbiome in cystic fibrosis: when to use antibiotics in the era of CFTR-modulator therapy
Justyna Milczewska, Zulfiya Syunyaeva, Aleksandra Żabińska-Jaroń, et al.
European Respiratory Review (2024) Vol. 33, Iss. 174, pp. 240068-240068
Open Access | Times Cited: 2
Beyond Kaftrio : mechanistic insights to maximize N1303K-CFTR rescue
Iwona Pranke, Valeria Capurro, B. Chevalier, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Elexacaftor/Tezacaftor/Ivacaftor Effectiveness in N1303K Variant in Adult People With Cystic Fibrosis
Mariane Gonçalves Martynychen Canan, Caroline Souza Sokoloski, Carolina Rossetti Severo, et al.
Archivos de Bronconeumología (2024) Vol. 60, Iss. 8, pp. 526-528
Closed Access | Times Cited: 1
Pharmacological rescue of the G85E CFTR variant by preclinical and approved modulators
Valeria Tomati, Valeria Capurro, Emanuela Pesce, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
The Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor (ETI) for People with CF Without a F508del Variant: A Systematic Review and Meta-Analysis
Dániel Lupas, Frank Y. Chou, Mohammad Abdullah Al Hakani, et al.
(2024)
Closed Access
Zukunft der Mukoviszidoseforschung und -therapie
Simon Y. Graeber, Marcus Mall
Monatsschrift Kinderheilkunde (2024) Vol. 172, Iss. 6, pp. 523-531
Closed Access
Bioassays zur Quantifizierung der „cystic fibrosis transmembrane conductance regulator“-Funktion
Sophia T. Pallenberg, Burkhard Tümmler
Monatsschrift Kinderheilkunde (2024) Vol. 172, Iss. 6, pp. 519-522
Closed Access
Exploring Turkey's mosaic of novel variants and complex alleles in cystic fibrosis genetics
Ceren Ayça Yıldız, Merve Selçuk, Şeyda Karabulut, et al.
Pediatric Pulmonology (2024)
Open Access
Theranostics vs theratyping or theranostics plus theratyping?
Margarida D. Amaral, Ines Pankonien
Journal of Cystic Fibrosis (2024)
Open Access
Bioassays zur Quantifizierung der „cystic fibrosis transmembrane conductance regulator“-Funktion
Sophia T. Pallenberg, Burkhard Tümmler
Zeitschrift für Pneumologie (2024) Vol. 21, Iss. 6, pp. 366-369
Closed Access
Zukunft der Mukoviszidoseforschung und -therapie
Simon Y. Graeber, Marcus Mall
Zeitschrift für Pneumologie (2024) Vol. 21, Iss. 6, pp. 370-378
Closed Access
Page 1

Scroll to top